NEWS

Sensome announces successful proof-of-concept adding its biological inte...

Sensome’s Clot‑Sensing Guidewire, Steered by Robocath’s Robotic Systems, Demonstrates Path Towards Physical AI 

Acandis GmbH Announces Start of Patient Recruitment for CARESTAR Study i...

Acandis GmbH, a leading German-based medical technology company specialising in medical devices for the treatment of neurovascular diseases, today announced the start of patient recruitment for the CARESTAR study following final positive approval from the responsible Ethics Committee. The study is registered on ClinicalTrials.gov (Identifier: NCT07166731).

Vesalio Expands International Neurovascular Portfolio with CE Mark of Ne...

Vesalio, a global leader in vascular intervention, today announced CE Mark certification and the European commercial launch of two new neurovascular devices: NeVa™ VS, for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), and the NeVa™ 3.0 mm Thrombectomy System for stroke. In addition, the Company received an additional U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indications of its neurovascular and peripheral aspiration catheters to include distal access.Plano, Texas – February 10, 2026

Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Su...

TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokesNEW ORLEANS & YOKNEAM, Israel--( BUSINESS WIRE )-- Rapid Medical™ , a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC) . 

Vesalio Receives FDA 510(k) Clearance of enVast, the First Stent-Based C...

The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.Plano, Texas – Dec 11, 2025

Vesalio Receives Two FDA 510(k) Clearances, Advancing Its Comprehensive...

The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.Plano, Texas – November 18, 2025

Acandis Supports ICARUS Study Advancing Treatment for Stroke Patients wi...

Basel, Switzerland – June 2025 – The University Hospital Basel, under the direction of Prof. Dr. Marios‑Nikos Psychogios, has officially launched the ICARUS study (“IntraCranial Atherosclerosis‑Related Large‑Vessel Occlusion Treated with Urgent Stenting”), with the first patient successfully enrolled in April 2025.

Expanding a Stroke Legacy: Terumo Neuro Announces US Commercial Availabi...

Terumo Neuro’s SOFIA™ Catheter Line is Backed By 10 Years of Proven Clinical Performance and Innovation – The New SOFIA™ 88 Catheter Offers Reliable Trackability, Proximal Stability and Vessel-Friendly Flexibility  

Philips launches intelligent 3D imaging in Europe to empower faster stro...

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the CE-marking of its latest SmartCT image reconstruction solution designed to support faster, more informed decision-making in the treatment of stroke and other neurovascular conditions. Already available in Japan and Canada, SmartCT is now CE-marked and available across Europe. The solution will be showcased at LINNC Paris 2025 (June 2–4), the world’s leading interventional neuroradiology congress.  

Q’Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™ Neur...

Fremont, CA – January 13, 2025 – Q’Apel Medical (Q’Apel), a privately held medical device company focused on revolutionizing neurovascular interventions, today announced it has received CE mark certification for its Armadillo SelectFlex™ Neurovascular Access System. The first-of-its-kind 7F system features the patented SelectFlex™ Technology and is indicated for the introduction of interventional devices into the neurovasculature.